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Abstract 
Hybrid leukemia is a clinical entity that includes: biphenotypic leukemia, characterized by the presence of markers of more 
than two lineages of a single tumor cell, bilineage leukemia, a combination of more than two lineage markers on two distinct blast 
cells, and biclonal leukemia, the concomitancy of more than two types of leukemic cells, derived from different clonal expansions. 
We present a case of a 7-year-old female diagnosed with bilineage leukemia. We propose a treatment for biphenotypic/bilineage 
leukemia in the cases with good prognostic factors. We suggest that hematopoietic stem cell transplantation is often not required for 
cure of these patients. 
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Introduction 
The diagnostic criteria for the classification of 
acute leukemia include: morphological appearance, 
immunophenotype blasts, cytogenetic and molecular 
analyses. The examination of the bone marrow aspirate 
w i l l  a l l o w ,  i n  m o s t  o f  t h e cases, to distinguish the 
lymphoblasts from the myeloblasts. Various cytochemical 
stains can distinguish lymphoblasts from myeloblasts: the 
lymphoblasts react positively with periodic acid-Schiff 
(PAS), with stains cytoplasmic glycogen, and the 
myeloblasts are myeloperoxidase positive in 75% of the 
patients. 
Fab ( French-American-British) morphological 
classification divides acute lymphoblastic leukemia (ALL) 
in three types (L1 , L2, L3) and nonlymphoblastic acute 
leukemia in eight types (M0 to M7). For acute 
lymphoblastic leukemia, this classification, except for the 
L3 type (Burkitt) identification, has lost its importance. 
The immunophenotyping of the leukemic blasts is 
essential to distinguish between B and T lymphoblastic 
line (Table 1). The immunological markers CD19, CD20, 
CD22, CD79a belong to line B, while CD2, CD3, CD5, 
CD7 are found on the surface of the T cells. 
Except for M0 and M7 (CD41, CD61), the 
myeloid line markers are: CD13, CD33, CD15, CD117 
and also the myeloperoxidase (MP0). According to the 
classic definition, acute leukemia is considered a 
malignant clonally proliferation of the hematopoietic 
precursors, on one line and so the blast cells frequently 
express markers of a single cell line (lineage fidelity). In a 
variable number of cases, an aberrant antigen expression 
can be found (lineage infidelity). 
 
Table 1. Immunological classification of acute 
lymphoblastic leukemia 
B line   
Pro-B  CD19+ and/or CD79a+ and/or CD22 cytoplasmic +, 
CD10-, cIg- 
Early 
preB 
CD10+ Cig- 
CD19+,cyt CD22+, HLADR+ 
Pre B  cIg  + 
CD19+, CD20+, CD24+, CD22+CD10+ 
HLADR+ 
B mature   sIg+ cIg- 
Express other B-cell antigens including CD19, CD20, CD24 HLADR 
 T line   
Pre T  CD7+( pro-T)  
Cd2+,CD5+,CD8+(pre-T)  
 
T mature  CD1a + ( T cortical ),  
CD35+,CD1a- ( Tmature) 
cIg= intracytoplasmic immunoglobulin 
cyt CD22= cytoplasmic CD22 
sIg= surface immunoglobulin 
 
This appears as the expression of one or more 
markers that belong to different cell lines. These cases 
were described as ALL expressing myeloid antigens (ALL 
My+) or acute myeloid leukemia (AML) with lymphoid 
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shown that the lineage infidelity has no prognostic 
significance [1]. 
 
Mixed acute leukemia (ambiguous lineage leukemia) 
In contrast to acute leukemia with lineage infidelity, the 
ambiguous lineage leukemia (hybrid leukemia) is a rare 
and heterogeneous group of acute leukemia, which 
presents the characteristics of both myeloid and lymphoid 
precursors [2]. Divergent morphological and 
immunophenotype features can be presented in a single 
blast population (biphenotypic leukemia) or in two 
morphologically distinct populations (bilineage leukemia). 
Cases of acute leukemia with lineage switch at relapse 
(from ALL to ALM or vice versa) have been reported as 
well. These forms can be considered as particular cases 
of acute bilineage leukemia [3,4]. The leukemic 
transformations occur in both cell lines, however, there is 
only one line expressed at diagnosis. In the case reported 
by Imatuki and col, the bone marrow went into remission 
after induction chemotherapy but the residual disease in 
the patient´s liver caused another phenotypic leukemia to 
arise [3]. The leukemogenic additional event would be the 
chemotherapy treatment itself. It has been postulated that 
a multipotent stem cell is capable of differentiating 
between more than one lineage. This feature of leukemic 
cells is described by the term ‘‘cancer stem cell’’. The 
classification of ambiguous lineage leukemia is presented 
in (Table 2) (according to the World Health Organization). 
The difference between acute biphenotypic leukemia and 
an ALL / AML with lineage infidelity is made through EGIL 
score (European Group for the Immunological 
Characterization of Leukemia), presented in (Table 3) [5]. 
To define a veritable biphenotypic acute leukemia the 
markers’ score on a least two lines must be greater than 
2. 
 
Table 2. Classification of ambiguous lineage leukemia (according to World Health Organization) 
undifferentiated acute leukemia    Absence  of specific markers of   myeloid or 
lymphoid  line 
 
Mixed acute leukemia with t (9;22) / bcr-abl    Mixed phenotype with translocation (9;.22) or bcr-
abl fusion 
Mixed acute leukemia with 11q23 rearrangements   Mixed phenotype with MLL gene rearrangements 
Mixed acute leukemia B / myeloid   Mixed  phenotype with 
B line  and myeloid markers without  bcr-abl fusion or 
 MLL gene rearrangements 
 
 
Mixed acute leukemia T / myeloid  
Mixed phenotype mixed with T 
and myeloid markers without bcr-abl 
fusion or MLL gene rearrangements 
Mixed acute leukemia T/B/ myeloid  Mixed phenotype with T, B and myeloid markers 
Mixed acute lymphoblastic leukemia T / B   Mixed  phenotype with B and T markers 
 
Other  natural killer cell lymphoma/leukemia 
 
 
Table 3. Immunological score (European Group for the Immunological Characterization of Leukemia) 
 
Score   B line   T line   Myeloid line 
2 points  CD79a 
CD22      
IgM cyt 
CD3  
Anti TCRαβ 
Anti TCRγδ        
Anti-MPO 
1 point  CD19 
CD10 
CD20 
CD2 
CD5 
CD8 
CD10 
CD13 
CD33 
CD117 
CDw65 
0,5 points  TdT 
CD24 
TdT  CD14 
CD15 
CD64 
 
Similarly to AML cases, acute leukemia with 
ambiguous lineage may occur de novo or may be 
secondary to chemotherapy and/or radiotherapy. The 
morphological appearance of blasts is heterogeneous (in 
one third of the cases there are lymphoblasts, and almost 
two thirds of cases are myeloblasts), very rarely there are 
two distinct populations. In cases with AML appearance, 
the M3, M6 and M7 types are exceptional, if not 
nonexistent [8]. According to the EGIL immunological 
score, several subgroups of BAL have been identified, 
namely: BAL with B lymphoid and myeloid markers 
coexpression (B/M), BAL with lymphoid markers T and B 
(T/B) and BAL with the coexpression of T/B/ myeloid [7]. 
The most frequent myeloid markers are CD33, CD13, 
Biphenotypic acute leukemia (BAL) 
occurs both in children and adults, but 
epidemiological data are rare. In a 
retrospective epidemiological study conducted 
on 693 adults and children cases with acute 
leukemia [6] BAL were detected in only 25 
cases (3,6%). Amal and al reported a 4,3% 
frequency of  biphenotypic leukemia in a study 
in children with acute leukemia [1]. The 
frequency in children seems to be less than in 
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CD11b. The most common forms are the BAL B/M, 
followed by BAL T/M.  BAL T/B is rare and BAL T/B/M is 
exceptional [8]. The cytogenetic and molecular analysis is 
essential for the prognosis and for the therapeutic attitude 
in all leukemia cases. The most common cytogenetic 
anomalies in BAL are t (9,22)(q34;q11), called the 
Philadelphia chromosome (Ph1) or bcr/abl 
rearrangements (type p190) and the rearrangements of 
11q23 band (frequently observed in infants with ALL). 
Translocation (9,22) leads to the loss of regulatory domain 
of ABL tyrosine kinase which makes changes in the 
activity of multiple pathways involved in cellular 
differentiation [9] . The MLL gene (11q23) encodes a large 
complex oncoprotein that regulates transcription. MLL 
(mixed lineage leukemia) maintains HOX gene expression 
during hematopoiesis. 
MLL translocations disrupt a breakpoint cluster 
region and fuse the 5´ portion of MLL with one of more 
than 50 different partner genes generating diverse 
leukemogenic fusion oncoproteins. 
Philadelphia chromosome is more common in 
adult cases, versus pediatric age (5%), but the frequency 
of t (9;22) in pediatric BAL is not documented. In a study 
of 35 children with BAL, Rubnitz and al reports the 
presence of an abnormal cariotype in only 29 of the 33 
studied cases. MLL gene rearrangements are observed in 
4 cases and were not otherwise identified if not for 
recurrent abnormalities, thus t (9;22)(10). 
In contrast to t (9,22), rearrangements of  the 
TEL-AML1 or t (12,21) are common in children and 
associate a favorable outcome. TEL-AML1+ patients have 
an increased expression of CD13 and CD33 compared 
with those who are TEL-AML1 negative. Over 60% of the 
children BAL have a TEL-AML1 rearrangement compared 
to only 25% of pediatric ALL. 
 
Prognosis 
Older studies reported a poor prognosis and a 
long-term survival rate of only 8% [2]. This would require 
a more intensive treatment with high doses and allografts. 
On the other hand, these studies mostly include adults 
with a high percentage of Ph1 cases. The situation is 
different in pediatric groups. Killick and al report a 2 year 
survival rate of 39% for all cases (adults and children), but 
six of the eight children with BAL were in remission at 2 
years after treatment. The authors have suggested that 
the prognosis in children with BAL does not differ from 
other forms of acute leukemia. 
The bilineage acute leukemia has a much lower 
frequency than biphenotypic acute leukemia, that is 1% of 
all cases (adults and children) and also a long-term 
remission was achieved in two of the 16 studied cases. In 
a study from St..Jude Children’s Hospital, over a period of 
20 years, we only identified 35 cases of BAL in children 
(2%), and, out of these, 49% are long term survivors. The 
analysis of cases demonstrates the difficulty of prediction 
in patients who respond better to the chemotherapy 
protocol for ALL versus AML. Rubnitz and al suggest that 
the stem cell transplantation should only be applied in 
cases with a percentage of marrow blasts over 1% after 
induction. For cases with a rate of blasts below 1%, the 
choice of treatment is more difficult [10]. 
Case report 
A 7-year-old female child was admitted to our 
unit on October 12, 2005 for the insidious onset of pallor 
and fatigue. On admission, the clinical picture showed 
pallor and moderated hepatosplenomegaly, without 
hemorrhagic manifestation. Blood cell count showed 
normochromic normocytic anemia (hemoglobin 7,4g/dl), 
moderate leukocytosis (16.000/µl) and moderate 
thrombocytopenia (82.000/ µl). Peripheral blood smear 
revealed 30% blast cells with morphologic appearance of 
L2 lymphoblasts. The hepatorenal, inflammatory and 
haemostatic balance was within normal limits. The 
cerebrospinal fluid examination was normal. The 
microscopic examination of the bone marrow aspirate 
showed a high cellular marrow with three distinct blast 
populations: myeloblasts (50%), promyeloblasts (10%) 
and L2 type lymphoblasts (20%). Flow cytometry revealed 
the positivity of the following immune markers: CD22+, 
CD19+, CD10+, CD13+, CD33+, HLA-DR+ and the 
cytochemical reaction was positive for myeloperoxidase. 
Chromosome analysis for the blast cells was normal. 
According to EGIL score, 4 points on each line of B 
lymphoid and myeloid line were obtained. From the 
immunological point of view, this case was an acute 
biphenotypic leukemia B/M and from the morphological 
point of view, this case was acute bilineage leukemia. In 
this case, the treatment was a combination of AML and 
ALL protocol, but with a different maintenance treatment. 
The treatment doses were calculated per m², and body 
surface area was of approximately 1m². The full treatment 
protocol is shown in (Table 4). 
 
 
Table 4. Treatment protocol in the case report 
Remission induction ( 2 cycles)  Dexametasone: 8mg i.v.; days 1-12(daily) 
Cytarabine:  100mg  days 1-3 and  200mg  days 4-9 
Vincristine 1,5mg ; day 1 and day 9 
Mitoxantrone: 12mg ;  days 4- 5 
Etoposide : 200 mg ; days 6 -8 
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Early intensification ( consolidation)  Cytarabine: 75 mg;  days 1-4; 8-11; 15-18; 29-32; 36-39; 43-
46( 6 cycles) 
6-Thioguanine : 60mg(po) ; days1-46(daily) 
Vincristine: 1,5mg ; days 1, 15, 29, 43 
Mitoxantrone: 12 mg ; days 1, 15, 29, 43 
Intensification high-dose cytarabine  Cytarabine: 3g ; days 1, 2, 3 
Mitoxantrone :12 mg ; days 3, 4, 5 
Intensification high-dose cytarabine  Cytarabine: 3g ; days 1, 2, 3 
Idarubicin: 10 mg ; days 3, 4, 5 
Reinduction therapy  Dexametasone: 8mg iv ; days 1- 33(daily) 
Vincristine: 1,5mg ; days  8, 15, 22, 29 
Daunorubicin : 30mg days 8, 15 ,22, 29 
L-Asparaginase : 5000U; days 12, 15, 18,   21 
 
Maintenance therapy  6-Thioguanine : 60mg (po); daily for  14 months 
Cytarabine : 80mg; days1,2,3,4( monthly for  12 months) 
Cyclophosphamide : 100mg: days 1,2,3,4 (monthly for 12 
months) 
 
Doses were calculed for a body surface area of 1 m2 
 
Remission induction was based on modified 
French society of oncopediatric protocol (1989). At the 
end of the first induction, the bone marrow aspirate 
smears showed a 7% residual blast infiltration. A second 
induction was started on day 15, using the same 
treatment, and, at the end of induction, the child was in 
complete remission (0% marrow blasts). Early 
intensification (consolidation), immediately after remission 
induction, belonged to the same protocol with dose 
adjustment of mitoxantrone (12mg instead of 8mg). The 
advantage of this treatment was its similarity to the 
consolidation therapy in childhood ALL treatment (BFM 
2002 protocol). Intensification therapy with high-dose 
cytarabine was consistent with modern protocol for AML. 
Reinduction therapy belonged to ALL-BFM 2002 protocol. 
The maintenance cures covered both blast populations. 
Prophylaxis of the central nervous system (CNS) 
leukemia was performed during the first year of treatment. 
Cessation of treatment was made on 01/08/2007. Until 
now, the infant has remained in complete remission (3 
years and 10 months after stopping the treatment). No 
sequelae of chemotherapy (neuropsychic and somatic 
development are normal as well as the cardiac and 
endocrine function) were identified. 
Discussion 
Mixed acute leukemia is a rare entity in children. 
It must be differentiated by acute leukemia with infidelity 
lineage, as both prognosis and therapeutic approach are 
different.  Published reports on mixed acute leukemia are 
limited so it is difficult to estimate the incidence. In the 
“Fundeni” Clinical Institute, Department of Pediatrics, 219 
new cases of acute leukemia were diagnosed between 
December 2005 and December 2010, of which 6 were 
BAL cases (2,7%) and  only one of these cases was a 
bilineage acute leukemia . The pathogeny of hybrid 
phenotype is complex.  Leukemic transformation occurs 
at the level of a multipotent progenitor. This progenitor 
has markers for more cell lines and a genetically diverse 
mosaic. The appearance of hybrid phenotype can be 
explained by the fact that the cell preserves some relics of 
the first attempts at differentiation. The differentiation of a 
cell line is accompanied by stop signal mechanisms for 
recombination and antigens expression for the other lines. 
If the stop signal events do not work, the differentiating 
process continues to operate simultaneously on different 
cell lines and thus to a cell clone with the markers that 
belong to several lines [11]. This lineage ambiguity model 
does not explain very well the appearance of bilineage 
leukemia. Is the leukemic transformation in these cases 
done at the level of a multipotent progenitor or it occurs 
simultaneously at the two precursor cells?  In other words, 
BAL is an entity separated from bilineage AL or the two 
are different expressions of a single process?  In the 
clinical case, which phenotipically corresponds to BAL 
B/M , there is a particularity: the presence of the 
promyelobasts , which in the published data are 
considered  extremely  rare.  Given the rarity of these 
cases, unlike the ALL and AML, there are no studies on 
prognostic factors. In principle, the known prognostic 
factors (age, hyperleukocitosis, pejorative cytogenetic 
anomalies, CNS leukemia and the initial response to 
treatment) can be applied in these cases. Our case is 
included in the forms with favorable prognosis: age 
between 1 year and 9 years, absence of pejorative 
cytogenetic anomalies, hyperleukocitosis and response to 
treatment. The major problem in these cases is the choice 
of therapeutic regimes. However, hematopoietic stem 
cells transplantation should be reserved in cases with t 
(9,22) or bcr/abl  fusion  and  MLL  rearrangements or in 
cases with  poor initial  response to treatment. Cases with 
favorable prognostic factors may only benefit from 
chemotherapy. The therapeutic line choice is still random, 
but in the future, a unitary therapeutic protocol might be 
developed. Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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